Receive the latest news, event invites, funding opportunities and more from the Ontario Institute for Cancer Research.
OICR Clinical Translation (CT) advances cancer research toward meaningful clinical impact. It supports preclinical and early clinical studies that develop and validate new approaches to detect, treat and monitor cancer at its earliest and most actionable stages. Through close partnership with patients, clinicians and researchers, CT helps ensure that clinically relevant, high-potential innovations are positioned for patient and healthcare impact.
OICR is inviting applications for CT’s Pre-Clinical Acceleration Team Award (Pre-CATA) funding stream. This program is intended to accelerate promising cancer biomarkers toward clinical application. It supports biomarkers that have undergone initial discovery and possess sufficient preliminary evidence to justify translational advancement.
Funding available
Pre-CATA levels
Funding is provided for two levels of biomarker projects:
Eligibility
Timeline
Questions?
Visit the FAQ page before contacting the OICR Scientific Secretariat office at ScientificSecretariat@oicr.on.ca.
To access funding opportunity resources, including: data sharing, open access and retention, eligible expenses, Equity, Diversity and Inclusion tactics in research, Ontario First mandate, patient partner payment policy and ReportNet instructions, please visit the bottom of the Funding Opportunities page.